by Raynovich Rod | Dec 10, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
Crude Trade Roils Markets-But Biotech Is Still A Safe Haven Second Worst Week of the Year-Late Day Trading Hit By Selling As the market becomes more volatile we should look at how the energy trade is affecting other asset classes. Certainly materials and industrials...
by Raynovich Rod | Oct 16, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
11/15/14 Speculative Small Cap Stocks-Stay Away Unless Your Are A Trader Nice profits were booked on our recent small cap picks but today the sell-off was “pronounced”: Celldex (CLDX) was down 21% to $13.10 after hitting a high near $18 on October 31....
by Raynovich Rod | Oct 13, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
10/14 …Update 3:10p Here come the sellers late in the day on schedule. Investors are trying to hold the fort. Oil down, treasuries up, JPMorgan misses off 0.43%. XLE off 0.57%, Gold steady at 1233, biotechs mixed but GILD down 5%, industrials and technology in...
by Raynovich Rod | Oct 9, 2014 | Biopharmaceuticals, Macro
Five Year Bull Market in Biotech We attended the Bio Investor Forum in San Francisco this week and it was well attended with over 600 participants and over 120 companies presenting. Attendees included VCs , investors, industry executives, bankers, and media. The Bio...
by Raynovich Rod | Sep 19, 2014 | Macro
Alibaba Should Open by 12 N EDT at $92.70, well above $68 IPO Price Price Discovery Underway with Trades moving toward $100 but now selling off to $93 up 36%. Alibaba (BABA) group may be sucking up a lot of cash from NASDAQ trades even with a option expiration. Money...
by Raynovich Rod | Sep 17, 2014 | Macro
Deflationary Signals or Just A Strong Dollar? Commodity stocks are getting crushed due to the strong dollar. Look at the XLE energy ETF down 10% from June highs when Middle East concerns were rising. Crude prices of course have also been crushed by the US shale play...
by Raynovich Rod | Jul 22, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Macro
Update 7/23 Biogen Idec (BIIB) Soars 11% on Earnings EPS at $3.49 vs est $2.83; Sales of MS drugs were $2.42B vs $1.72B last year. Our large cap portfolio is now up 15% YTD with less risk than mid and small caps. One analyst thinks PBYI will be acquired but watch out...
by Raynovich Rod | Jul 15, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio, Macro
Update 8PM EDT NASDAQ Holds Losses to 0.54%-Futures Stable Biotech Damage Across the Sector-Rayno Life Science Portfolio Notes Large Caps off about 2% (FBT), but Gilead (GILD) down only 0.95% and Roche (RHHBY) up 0.28%. Rayno Biopharma stocks all red down 3-4% with...
by Raynovich Rod | Jun 18, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Update June 19.. 3:10 p EDT Ten Yr 2.62%, U.S.equities flat,biotech mixed, jobless claims down. Japanese and European equities up. Iraq on front page. GOLD Up $41 Breaks Through Resistance at $1300 Gold futures rose on technicals, Middle East turmoil, a weak dollar...
by Raynovich Rod | Jun 12, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
NASDAQ Off 0.8% On Disappointing Economic Data and Spiking Crude Islamic militants took major cities in Iraq causing a spike in oil to $106. The energy sector rallied 0.7% with many smaller players soaring over 4%. The energy sector is very strong up 10% YTD....
